Skip to Content


Active Substance: rimonabant
Common Name: rimonabant
ATC Code: A08AX01
Marketing Authorisation Holder: sanofi-aventis
Active Substance: rimonabant
Status: Withdrawn
Authorisation Date: 2006-06-19
Therapeutic Area: Obesity
Pharmacotherapeutic Group: Antiobesity preparations, excl. diet products

Therapeutic Indication

As an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/m2), or overweight patients (BMI > 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

The marketing authorisation for Zimulti has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.